Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.8% in the 1st quarter, HoldingsChannel reports. The firm owned 95,180 shares of the medical equipment provider’s stock after selling 10,329 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Zimmer Biomet were worth $8,606,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. DV Equities LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Monetary Solutions Ltd purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $31,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $32,000. Finally, Grove Bank & Trust boosted its holdings in Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Up 3.8%

Shares of NYSE:ZBH opened at $93.57 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The stock has a market cap of $18.10 billion, a P/E ratio of 24.30, a P/E/G ratio of 2.65 and a beta of 0.46. The firm has a fifty day moving average price of $86.99 and a 200 day moving average price of $89.82.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the prior year, the company earned $1.81 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Analyst Ratings Changes

ZBH has been the topic of several recent research reports. Barclays cut their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Stifel Nicolaus lowered their price objective on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citizens Jmp lowered their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Finally, Truist Financial reissued a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.